Eli Lily, a pharmaceutical giant to release a diabetes drug. Pharmaceutical giant Eli Lilly said Thursday it will seek approval to add its diabetes drug to the buzzy US weight loss market after achieving promising results in a new clinical trial Tirzepatide, currently approved to treat type 2 diabetes under the name Mounjaro, is taken once a week as an injection. Eli Lilly said its trial was conducted over a period of 72 weeks on just over 900 overweight or obese participants with type 2 diabetes. Those who received the highest dosage lost an average of 15.7 percent of their body weight, or 34.4 pounds (15.6 kilograms), the company said, with the most common side effects being mild to moderate gastrointestinal issues such as nausea and diarrhea. Like other drugs which have recently become popular for weight loss, tirzepatide mimics the gastrointestinal hormone GLP-1, activating receptors in the brain involved in appetite regulation. Though Mounjaro has only been approved in the Unite
Comments
Post a Comment